Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $23

2026-04-08
Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $30 to $23.

Amphastar Pharmaceuticals Authorizes $50M Increase To Its Share Buyback Program-8k

2026-03-16

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-16
Amphastar Pharmaceuticals, Inc. (AMPH) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 PM EDTCompany ParticipantsWilliam Peters - CFO,...

Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here

2026-03-16
Amphastar (AMPH) Buy: 81% upside to $33 fair value. 2026 margin pressure but Baqsimi and new launches drive growth.

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference - Slideshow

2026-03-13
2026-03-13. The following slide deck was published by Amphastar Pharmaceuticals, Inc.

Amphastar Nanjing Signs 5-Year Supply Agreement With Nanjing Letop Biotechnology For Chemical Intermediates With Payments In Chinese Yuan

2026-03-06
Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement. Supply Agreement. On March 3, 2026, (the "Effective Date"), Amphastar Nanjing Pharmaceuticals, Inc. ("ANP"), the

Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label

2026-02-28

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $30

2026-02-27
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Overweight and lowers the price target from $34 to $30.

Amphastar Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results. Also, Needham maintained a Buy rating on the stock but lowered its price target from $34 to $30.

2026-02-27

Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session

2026-02-27